Key facts
- This page summarizes Ronald Peck's Form 4 filing for ARVINAS, INC. (ARVN).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Feb 2024, 18:34.
Ronald Peck - 23 Feb 2024 Form 4 Insider Report for ARVINAS, INC. (ARVN)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- ARVN
- Reported as of
- 23 Feb 2024
- Net transaction value
- -$79,938
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2024, 18:34:14 UTC
- Prior SEC filing
- 14 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jared Freedberg, as attorney-in-fact for Ronald Peck
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ronald Peck filed Form 4 for ARVINAS, INC. (ARVN) on 27 Feb 2024.
Change
- Previous filing in this sequence was filed on 14 Aug 2023.
- Current net transaction value: -$79,938.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARVN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +39,250
- Change %
- +131%
- Price
- $0.000000
- Shares after
- 69,215
- Date
- 23 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
ARVN
transaction
Common Stock
Sale
- Transaction value
- $79,938
- Shares
- -1,699
- Change %
- -2.5%
- Price
- $47.05
- Shares after
- 67,516
- Date
- 23 Feb 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARVN
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +58,100
- Change %
- Price
- $0.000000
- Shares after
- 58,100
- Date
- 23 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 58,100
- Exercise price
- $47.00
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The restricted stock units (each, an "RSU") were granted by the Issuer on February 23, 2024, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over two years: 1/2 of the shares underlying the award shall vest on February 23, 2025, with the remainder of the shares vesting on February 23, 2026.
Footnote F2
This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.
Footnote F3
The option was granted by the Issuer on February 23, 2024, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on February 23, 2025, with the remainder of the shares vesting on February 23, 2026.